BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

336 related articles for article (PubMed ID: 25624485)

  • 1. Direct inhibition of oncogenic KRAS by hydrocarbon-stapled SOS1 helices.
    Leshchiner ES; Parkhitko A; Bird GH; Luccarelli J; Bellairs JA; Escudero S; Opoku-Nsiah K; Godes M; Perrimon N; Walensky LD
    Proc Natl Acad Sci U S A; 2015 Feb; 112(6):1761-6. PubMed ID: 25624485
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Selective apoptosis-inducing activity of synthetic hydrocarbon-stapled SOS1 helix with d-amino acids in H358 cancer cells expressing KRAS
    Xu LL; Li CC; An LY; Dai Z; Chen XY; You QD; Hu C; Di B
    Eur J Med Chem; 2020 Jan; 185():111844. PubMed ID: 31706640
    [TBL] [Abstract][Full Text] [Related]  

  • 3. mTORC1 upregulation via ERK-dependent gene expression change confers intrinsic resistance to MEK inhibitors in oncogenic KRas-mutant cancer cells.
    Komatsu N; Fujita Y; Matsuda M; Aoki K
    Oncogene; 2015 Nov; 34(45):5607-16. PubMed ID: 25703330
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting Son of Sevenless 1: The pacemaker of KRAS.
    Kessler D; Gerlach D; Kraut N; McConnell DB
    Curr Opin Chem Biol; 2021 Jun; 62():109-118. PubMed ID: 33848766
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SOS1-inspired hydrocarbon-stapled peptide as a pan-Ras inhibitor.
    Li A; Li X; Zou J; Zhuo X; Chen S; Chai X; Gai C; Xu W; Zhao Q; Zou Y
    Bioorg Chem; 2023 Jun; 135():106500. PubMed ID: 37003134
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Small Molecule-Mediated Activation of RAS Elicits Biphasic Modulation of Phospho-ERK Levels that Are Regulated through Negative Feedback on SOS1.
    Howes JE; Akan DT; Burns MC; Rossanese OW; Waterson AG; Fesik SW
    Mol Cancer Ther; 2018 May; 17(5):1051-1060. PubMed ID: 29440291
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Unique dependence on Sos1 in
    You X; Kong G; Ranheim EA; Yang D; Zhou Y; Zhang J
    Blood; 2018 Dec; 132(24):2575-2579. PubMed ID: 30377195
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of Son of Sevenless Homologue 1 (SOS1): Promising therapeutic treatment for KRAS-mutant cancers.
    Chen T; Tang X; Wang Z; Feng F; Xu C; Zhao Q; Wu Y; Sun H; Chen Y
    Eur J Med Chem; 2023 Dec; 261():115828. PubMed ID: 37778239
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design of Orally-bioavailable Tetra-cyclic phthalazine SOS1 inhibitors with high selectivity against EGFR.
    He H; Chen R; Wang Z; Qing L; Zhang Y; Liu Y; Pan W; Fang H; Zhang S
    Bioorg Chem; 2023 Jul; 136():106536. PubMed ID: 37054529
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Induction of the Ras activator Son of Sevenless 1 by environmental pollutants mediates their effects on cellular proliferation.
    Pierre S; Bats AS; Chevallier A; Bui LC; Ambolet-Camoit A; Garlatti M; Aggerbeck M; Barouki R; Coumoul X
    Biochem Pharmacol; 2011 Jan; 81(2):304-13. PubMed ID: 20950586
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of potent SOS1 inhibitors that block RAS activation via disruption of the RAS-SOS1 interaction.
    Hillig RC; Sautier B; Schroeder J; Moosmayer D; Hilpmann A; Stegmann CM; Werbeck ND; Briem H; Boemer U; Weiske J; Badock V; Mastouri J; Petersen K; Siemeister G; Kahmann JD; Wegener D; Böhnke N; Eis K; Graham K; Wortmann L; von Nussbaum F; Bader B
    Proc Natl Acad Sci U S A; 2019 Feb; 116(7):2551-2560. PubMed ID: 30683722
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activation of the RAS/RAF/ERK signaling pathway contributes to resistance to sunitinib in thyroid carcinoma cell lines.
    Piscazzi A; Costantino E; Maddalena F; Natalicchio MI; Gerardi AM; Antonetti R; Cignarelli M; Landriscina M
    J Clin Endocrinol Metab; 2012 Jun; 97(6):E898-906. PubMed ID: 22442268
    [TBL] [Abstract][Full Text] [Related]  

  • 13. One Atom Makes All the Difference: Getting a Foot in the Door between SOS1 and KRAS.
    Ramharter J; Kessler D; Ettmayer P; Hofmann MH; Gerstberger T; Gmachl M; Wunberg T; Kofink C; Sanderson M; Arnhof H; Bader G; Rumpel K; Zöphel A; Schnitzer R; Böttcher J; O'Connell JC; Mendes RL; Richard D; Pototschnig N; Weiner I; Hela W; Hauer K; Haering D; Lamarre L; Wolkerstorfer B; Salamon C; Werni P; Munico-Martinez S; Meyer R; Kennedy MD; Kraut N; McConnell DB
    J Med Chem; 2021 May; 64(10):6569-6580. PubMed ID: 33719426
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting RAS oncogenesis with SOS1 inhibitors.
    Hillig RC; Bader B
    Adv Cancer Res; 2022; 153():169-203. PubMed ID: 35101230
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cell type-specific importance of ras-c-raf complex association rate constants for MAPK signaling.
    Kiel C; Serrano L
    Sci Signal; 2009 Jul; 2(81):ra38. PubMed ID: 19638615
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification and Characterization of Oncogenic
    Cai D; Choi PS; Gelbard M; Meyerson M
    Mol Cancer Res; 2019 Apr; 17(4):1002-1012. PubMed ID: 30635434
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SUMOylation of Grb2 enhances the ERK activity by increasing its binding with Sos1.
    Qu Y; Chen Q; Lai X; Zhu C; Chen C; Zhao X; Deng R; Xu M; Yuan H; Wang Y; Yu J; Huang J
    Mol Cancer; 2014 Apr; 13():95. PubMed ID: 24775912
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Translational relevance of SOS1 targeting for KRAS-mutant colorectal cancer.
    Alem D; Yang X; Beato F; Sarcar B; Tassielli AF; Dai R; Hogenson TL; Park MA; Jiang K; Cai J; Yuan Y; Fernandez-Zapico ME; Tan AC; Fleming JB; Xie H
    Mol Carcinog; 2023 Jul; 62(7):1025-1037. PubMed ID: 37042566
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ribonucleoprotein HNRNPA2B1 interacts with and regulates oncogenic KRAS in pancreatic ductal adenocarcinoma cells.
    Barceló C; Etchin J; Mansour MR; Sanda T; Ginesta MM; Sanchez-Arévalo Lobo VJ; Real FX; Capellà G; Estanyol JM; Jaumot M; Look AT; Agell N
    Gastroenterology; 2014 Oct; 147(4):882-892.e8. PubMed ID: 24998203
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mutations of p53 and KRAS activate NF-κB to promote chemoresistance and tumorigenesis via dysregulation of cell cycle and suppression of apoptosis in lung cancer cells.
    Yang L; Zhou Y; Li Y; Zhou J; Wu Y; Cui Y; Yang G; Hong Y
    Cancer Lett; 2015 Feb; 357(2):520-6. PubMed ID: 25499080
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.